VIDEO – Sotorasib for chemorefractory mCRC

Cancer

6 Nov 2023

Dr Filippo Pietrantonio, Medical Oncologist, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy, discusses the primary results from the Phase 3 CodeBreak 300 trial, which investigated sotorasib plus panitumumab vs. standard of care in patients with chemorefractory KRAS G12C-mutated metastatic colorectal cancer.

Already a member?

Login to keep reading.

OR
Email me a login link